Neural dynamics of short and medium-term motor control effects of levodopa therapy in Parkinson's disease

Artificial Intelligence in Medicine

Volumn 13, Issue 1-2, 1998, Pages 57-79

  Contreras Vidal, José L ^a   Poluha, Patricia ^b   Teulings, Hans Leo ^a   Stelmach, George E ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

Basal ganglia; Bradykinesia; Dopamine; Handwriting; Levodopa; Micrographia; Neural network; Neurotransmitters

Indexed keywords

BRAIN; CELLS; DISEASES; PATIENT TREATMENT; RNA;

BASAL GANGLIA; BRADYKINESIA; DOPAMINE; LEVODOPA; MICROGRAPHIA; MOTOR CONTROL EFFECTS; NEURAL DYNAMICS; PARKINSON DISEASE;

NEURAL NETWORKS;

LEVODOPA;

ARTICLE; ARTIFICIAL NEURAL NETWORK; BRADYKINESIA; COMPUTER MODEL; COMPUTER SIMULATION; DOPAMINE METABOLISM; DOPAMINERGIC TRANSMISSION; DOSE TIME EFFECT RELATION; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; HANDWRITING; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

AGED; ANTIPARKINSON AGENTS; COMPUTER SIMULATION; DOPAMINE; HUMANS; LEVODOPA; MALE; MODELS, NEUROLOGICAL; NEURAL NETWORKS (COMPUTER); NEUROPEPTIDES; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE;

EID: 0032078777     PISSN: 09333657     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0933-3657(98)00004-9     Document Type: Article

References (38)

1. Alexander G.E., DeLong M.R., Strick P.L. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 9:1986;357-381.
2. Bannon M.J., Elliot P.J., Bunney E.B. Striatal tachykinin biosynthesis: regulation of mRNA and peptide levels by dopamine agonists and antagonists. Mol Brain Res. 3:1987;31-37.
3. Bullock D., Grossberg S., Mannes C. A neural network model for cursive script production. Biol Cybern. 70:1993;15-28.
4. Bullock D., Grossberg S. Neural dynamics of planned arm movements: emergent invariants and speed-accuracy properties during trajectory formation. Psychol. Rev. 95:1988;49-90.
5. Contreras-Vidal JL, Stelmach GE. Motor processing in Parkinson's disease, in: Boller F, Grafman J, editors. Handbook of Neuropsychology, vol. 8, chapter 8. Amsterdam: Elsevier, 1997:149-165.
6. Contreras-Vidal J.L., Stelmach G.E. A neural model of basal ganglia-thalamo cortical relations in normal and parkinsonian movement. Biol Cybern. 73:1995;467-476.
7. Contreras-Vidal JL, Tenlings HL, Stelmach GE. A neural network model of movement production in Parkinson's disease and Huntington's disease. In: Regia J, Berdt R, Ruppin E, editors. Neural Modeling of Brain and Cognitive Disorders. Singapore: World Scientific, 1996:377-392.
8. Contreras-Vidal J.L., Teulings H.L., Stelmach G.E. Micrographia in Parkinson's disease. NeuroReport. 6:1995;2089-2092.
9. Fink J.S. Neurobiology of basal ganglia receptors. Clin Neurosci. 1:1993;27-35.
10. Gerfen C.R. Segregation of D1 and D2 dopamine receptor mRNA in separate populations of striatal neurons. Soc Neurosci Abst. 19:1993;133.
11. Gerfen C.R. The neostriatal mosaic: Multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci. 15:1992;285-320.
12. Gerfen C.R., McGinty J.F., III Young W.S. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J Neurosci. 11:1991;116-1031.
13. Giladi N., McMahon D., Przedborski S., Flaster E., Guillory S., Kostic V., Fahn S. Motor blocks in Parkinson's disease. Neurology. 42:1992;333-339.
14. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13:1990;244-254.
15. Grossberg S. Some normal and abnormal behavioral syndromes due to transmitter gating of opponent processes. Biol Psychiatr. 19:1984;1075-1117.
16. Hacisalihzade S.S., Mansour M., Albani C. Optimization of symptomatic therapy in Parkinson's disease. IEEE Trans Biomed Eng. 36:1989;363-372.
17. Hazrati L.N., Parent A., Mitchell S., Haber S.N. Evidence for interconnections between the two segments of the globus pallidus in primates: a PHA-L anterograde tracing study. Brain Res. 533:1990;171-175.
18. Hoover J.E., Strick P.L. Multiple output channels in the basal ganglia. Science. 259:1993;819-821.
19. Johnson M.T.V., Mendez A., Kipnis A.N., Silverstein P., Zwiebel F., Ebner T.J. Acute effects of levodopa on wrist movement in Parkinson's disease: Kinematics, volitional EMG modulation, and reflex amplitude modulation. Soc Neurosci Abstr. 20:1994;1406.
20. Knopp W., Paulson G., Allen J.N., Smeltzer D., Brown F.D., Kose W. Parkinson's disease: L-Dopa treatment and handwriting area. Curr Ther Res. 12:1970;115-125.
21. LaHoste GJ, Marshall JF. Dopamine receptor interactions in the brain. In: Stone TW, editor. CNS Neurotransmitters and Neuromodulators: Dopamine. Boca Raton, Florida: CRC Press, 1996:107-119.
22. LaHoste G.J., Marshall J.F. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in receptor density. Synapse. 12:1992;14-26.
23. LaHoste G.J., Marshall J.F. The role of dopamine in the maintenance and breakdown of D1/D2 synergism. Brain Res. 611:1993;108-116.
24. Lewitt P.A. Micrographia as a focal sign of neurological disease. J Neurol Neurosurg Psychiatr. 51:1983;1152-1153.
25. Margolin D.I., Wing A.M. Agraphia and micrographia: Clinical manifestations of motor programming and performance disorders. Acta Psychol. 54:1983;263-283.
26. McLennan J.E., Nakano K., Tyler H.R., Schwab R.S. Micrographia in Parkinson's disease. J Neurol Sci. 15:1972;141-152.
27. Montgomery E.B., Nuessen J., Gorman D.S. Reaction time and movement velocity abnormalities in parkinson's disease under different task conditions. Neurology. 41:1991;1476-1481.
28. Neve K.A., Neve R.L., Fidel S., Janowsky A., Higgins G.A. Increased abundance of alternatively spliced forms of D2 dopamine receptor mRNA after denervation. Proc Natl Acad Sci USA. 88:1991;2802-2806.
29. Nisenbaum L.K., Kitai S.T., Crowley W.R., Gerfen C.R. Temporal dissociation between changes in striatal enkephalin and substance P messenger RNAs following striatal dopamine depletion. Neuroscience. 60:1994;927-937.
30. Nutt J.G. Pharmacotherapy of Parkinson's disease. Clin Neurosci. 1:1993;64-68.
31. Nutt J.G., Woodward W.R., Hammerstad J.P., Carter J.H., Anderson J.L. The 'on-off' phenomenon in Parkinson's disease: Relation to levodopa absorption and transport. New Engl J Med. 310:1988;483-488.
32. Parent A., Hazrati L.-N. Functional anatomy of the basal gangli. I. The corticobasal ganglia-thalmo-cortical loop. Brain Res Rev. 20:1995;91-127.
33. Schwab R.S. Limitations in treatment of Parkinson's disease. New Engl J Med. 279:1968;943-946.
34. Smith Y., Parent A. Neurons of the subthalamic nucleus in primates display glutamate but not GABA immunoreactivity. Brain Res. 453:1988;353-356.
35. Suri R. Motor Control in Parkinson's disease. ETH Zurich: vdf Hochschulverlag AG, 1996.
36. Teulings H.L., Stelmach G.E. Control of stroke size, peak aceleration and stroke duration in Parkinsonian handwriting. Human Movement Sci. 10:1991;315-333.
37. Teulings H.L., Contreras-Vidal J.L., Stelmach G.E. Coordination of fingers, wrist, and arm in parkinsonian handwriting. Exp Neurol. 146:1997;159-170.
38. Wooten G.F. Progress in understanding the pathophysiology of treatmentrelated fiuctuations in Parkinson's disease. Ann Neurol. 24:1988;363-365.